Regeneron Forges a US$100 M Oncology Partnership with Bluebird Bio

By Michelle Liu

Pharma Deals Review: Vol 2018 Issue 8 (Table of Contents)

Published: 17 Aug-2018

DOI: 10.3833/pdr.v2018.i8.2349     ISSN: 1756-7874

Section: Research & Development



Pushing forward in its cancer immunotherapy research, Regeneron Pharmaceuticals has struck a deal with Bluebird Bio to develop new cancer cell therapies using Regeneron’s VelociSuite® platform technologies and Bluebird Bio’s gene therapy knowledge...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details